Refined graft-versus-host disease (GVHD)/relapse-free survival (GRFS) considers main outcomes of allogeneic stem cell transplant (HSCT), estimating long-term survival without significant morbidity as a surrogate of HSCT success. We compared GRFS in 5059 adults with acute myeloid leukemia (AML), undergoing HSCT in first complete remission from 2000 to 2015 either from a matched sibling (MSD, n = 3731) or unrelated donor (MUD, n = 1328). Median age was 49 (range: 18-76) years. Median follow-up was 32 and 60 months in MSD and MUD, respectively (p < 0.01). Compared to MSD, at 4 years, MUD recipients had lower GRFS, with higher NRM, grade III-IV acute GVHD, and extensive chronic GVHD (HR: 1.42, p < 0.01). We also performed a risk factor analyses, showing unfavorable cytogenetics (HR: 1.42, p < 0.01) and peripheral blood as stem cell source (HR: 1.22, p < 0.01) associated to lower GRFS, while this was higher with in vivo T-cell depletion (TCD, HR: 0.73, p < 0.01) and shorter time from diagnosis to HSCT (HR 0.96, p < 0.01). Different factors, modifiable or not, such as donor type, stem cell source, disease biology, and in vivo TCD, impact on GRFS and this may guide in the future transplant choices to improve morbidity and long-term quality of life.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) may represent one possible option to treat patients diagnosed with acute myeloid leukemia (AML) with intermediate or high-risk cytogenetics in complete remission (CR) [1] . In patients lacking a matched sibling HLAidentical donor (MSD), the subsequent preferred option is represented by HLA-matched (10/10) unrelated donors (MUD) who are widely available from international registries [2] .
Several studies reported a stronger graft vs leukemia effect and a lower relapse incidence (RI) when HSCT is performed from MUD, explained by the presence of mismatches in minor histocompatibility antigens [3, 4] . This is often counterbalanced by a higher incidence of graft-versushost disease (GVHD) and a higher non-relapse mortality (NRM) [5, 6] . All these individual complications (i.e., GHVD, relapse or death) significantly impact HSCT outcomes with impairment of quality of life and long-term survival [7, 8] . Classical endpoints such as leukemia-free survival (LFS) or GVHD only reflect some of the main HSCT outcomes, but each of these outcomes is clinically meaningful and closely linked to each other, so that each one should be taken into account when assessing transplant outcomes. The GVHD-relapse-free survival (GRFS) parameter has been initially developed by Holtan et al. [9] as a useful composite endpoint contemporarily taking into account the combination of all these clinical events in one single outcome, which should represent a valid measure of survival without ongoing morbidity, reflecting quality of life after HSCT. The GRFS was initially defined as the time when the first event among grade III-IV acute GVHD (aGVHD), chronic GVHD (cGVHD) requiring systemic immunosuppressive treatment, disease relapse or death from any other cause occurred during the first year after HSCT.
Subsequently, Ruggeri et al. [10] developed the refined GRFS, considering occurrence of extensive cGVHD up to 3 years after HSCT.
Furthermore, the type of donor is not the only factor that may impact on GVHD and relapse. The conditioning regimen can influence RI and NRM while source of stem cell may have an impact on GVHD incidence [11, 12] .
The aim of the current retrospective study was to compare GRFS after HSCT from either a MSD or MUD in adults with AML with intermediate or unfavorable karyotype in first complete remission (CR), and secondarily to also perform a risk factor analysis for GRFS to explore any independent effect of clinical factors on this composite endpoint.
Methods

Definitions and endpoints
We retrospectively analyzed patients (≥18 years) diagnosed with de novo AML with intermediate or unfavorable karyotype who underwent their first allogeneic HSCT in CR1 between 2000 and 2015 from either a fully matched sibling (MSD) or matched (10/10) unrelated donor (MUD). Of note, in the MUD group, selected were only patients for which details about HLA match were available (match considered at HLA-A, HLA-B, HLA-C, HLA-DQ, HLA-DRB1).
The EBMT registry is a working group of more than 500 transplant centers that are required to report all consecutive HSCT and follow-up data once a year. Each patient provides consent for transplant according to the declaration of Helsinki. This study was approved by the Review Board of the EBMT.
Patients were stratified as having intermediate or unfavorable karyotype according to previous definitions [13] , while CR was defined as reported by Cheson et al. [14] .
Conditioning regimen was defined as reduced intensity (RIC) in the case of administration of total body irradiation (TBI) at a dose lower than 6 Gray (Gy), or oral busulfan lower than 8 mg/kg, or intravenous busulfan lower than 6.4 mg/kg, while it was defined myeloablative (MAC) when it contained TBI or busulfan at greater doses. In vivo T-cell depletion (TCD), essentially rabbit anti-T-lymphocyte immune globulin (ATG), was mainly used in MUD recipients.
Neutrophil engraftment was defined as the first of three consecutive days with an absolute neutrophil count greater than 0.5 × 10 9 /L. Acute and chronic GVHD were diagnosed and graded according to standard criteria [15] .
Primary endpoint of the study was to compare refined GRFS after HSCT from MSD or MUD in patients with AML with intermediate or unfavorable cytogenetics. Refined GRFS was defined, according to report from Ruggeri et al. [10] , as being alive with neither grade III-IV aGVHD, extensive cGVHD nor disease relapse at any time point. All events occurring from allo-HSCT to last followup were considered when calculating GRFS. Among secondary endpoints, a risk factor analysis was performed, with adjustments made according to differences between the two groups. Overall survival (OS) was defined as the probability of being alive at any time point, while LFS was defined as the probability of being alive and disease-free at any time point; both death and relapse were considered events, and patients who were alive and in CR were censored at their last follow-up. Non-relapse mortality was defined as any death not related to relapse.
Statistical analysis
Median values and ranges were used for continuous variables and percentages for categorical variables. Patient-, disease-, and transplant-related variables of the groups were compared using chi-square or Fischer exact test for categorical variables, and Mann-Whitney test for continuous variables. The probabilities of OS, GRFS, and LFS were calculated using the Kaplan-Meier method and the log-rank test for univariate comparisons [16] .
Neutrophil engraftment, acute and chronic GVHD, RI, and NRM were calculated by using the cumulative incidence (CI) estimator to accommodate competing risks. For NRM, relapse was the competing risk, and for RI the competing risk was death without relapse. Comparisons between CI curves were performed using the Gray test. After adjusting for differences between the two groups, multivariate analyses was performed using Cox proportional hazards regression model for GRFS, LFS and OS, and Fine and Gray's proportional hazards regression model for engraftment, GVHD, NRM, and relapse [17] . Of note, as the primary objective of the study was to compare outcomes according to donor type, regression models include all factors differing between groups and variables associated with outcome in univariate analyses.
P-values were two-sided. Statistical analyses were performed with the SPSS 21 (SPSS Inc./IBM, Armonk, NY, USA) and R 3.0 (R Development Core Team, Vienna, Austria) software packages.
Results
Patient and transplant characteristics
Baseline characteristics are summarized in Table 1 . Briefly, 5059 patients fulfilled inclusion criteria; of these, 3731 were transplanted with a MSD and 1328 with a MUD. Median age at HSCT was 49 (range: 18-76) years.
There were some differences between the two groups. Compared to MSD, MUD recipients were older (52 vs 48 years, p < 0.01), had a longer interval from diagnosis to HSCT (168 vs 140 days, p < 0.01) and a shorter follow-up (32 vs 60 months, p < 0.01). Intermediate cytogenetics was the most represented category in both groups, with a higher proportion in the MSD recipients group (79 vs 69%, p < 0.01), with similar distribution of MAC and RIC regardless donor type. Peripheral blood stem cell (PBSC) was the most used graft source in both groups (MUD 79 vs MSD 74%, p < 0.01). Seropositivity for CMV was higher in MSD (59 vs 38%, p < 0.01). Differences were also observed in the conditioning regimen intensity: MAC was used in 59 and 47% of MSD and MUD recipients, respectively (p < 0.01). In vivo TCD was mainly used in MUD recipients (72 vs 26% in MSD, p < 0.001). Survival outcomes at 4 years are reported in Fig. 1 .
GRFS and risk factor analysis
Details of uni-and multivariate analyses for GRFS are reported in Supplemental Table and Table 2 , respectively. At 4 years, there were no differences for GRFS in MSD and MUD recipients (43 vs 44%, p = 0.90) in univariate analysis. However, a lower GRFS was found in MUD recipients in the adjusted multivariate analysis (hazard ratio (HR): 1.19, confidence interval (CI): 1.07-1.31, p < 0.01) (Fig. 2a) . Risk factor analysis for GRFS showed that patients with unfavorable cytogenetics at diagnosis (HR: 1.42, CI: 1.31-1.54, p < 0.01), male recipients receiving graft from female donors (HR: 1.23, CI: 1.13-1.35, p < 0.01), an incremental age of more than 10 years (HR: 1.12, CI: 1.07-1.31, p < 0.01) and the use of PBSC (HR: 1.22, CI: 1.11-1.35, p < 0.01) were associated to a lower GRFS, while a longer interval from diagnosis to HSCT was associated to a higher GRFS (HR: 0.96, CI: 0.94-0.98, p < 0.01).
Moreover, regardless of donor type, patients receiving in vivo TCD experienced a better GRFS (HR: 0.73, CI: 0.66-0.79, p < 0.01, Fig. 2b ) in multivariate analysis.
When comparing the first GRFS event occurring according to donor type, we found a similar distribution among the two groups, with relapse accounting for a greater proportion of GRFS events (42% in MSD and 40% in MUD recipients, Fig. 3a) , followed by cGVHD (34% in MSD and 29% in MUD recipients, Fig. 3a) .
When looking for interactions between donor types and other covariates, no significant interactions were found. However, considering the worse outcomes in patients not receiving in vivo TCD, we also performed a subgroup HR hazard ratio, CI confidence interval, GRFS graft-versus-host disease-free relapse-free survival, RI relapse incidence, NRM nonrelapse-mortality, LFS leukemia-free survival, OS overall survival, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versushost disease, MUD matched unrelated donor, vs versus, MSD matched sibling donor, y years, HSCT hematopoietic stem cell transplantation, dx diagnosis, mo months, PBSC peripheral blood stem cells, BM bone marrow, RIC reduced intensity conditioning regimen, MAC myeloablative conditioning regimen, CMV cytomegalovirus, TCD T-cell depletion analysis on the use of in vivo TCD regardless of donor type.
In both MSD and MUD recipients not receiving in vivo TCD the main GRFS event was cGVHD, accounting for 38% and 36% in MSD and MUD recipients, respectively, followed by disease relapse in 36% of MSD and 30% of MUD recipients. On the other hand, in both MSD and MUD recipients receiving in vivo TCD, relapse accounted for a greater proportion of GRFS events (57% and 44%), but a lower rate of cGVHD was observed (21% and 26%, Fig. 3b ). Causes of death were similarly distributed in both MSD and MUD recipients, with disease recurrence being the main cause in 56 and 49% of cases, respectively, while infections accounted for 14% and 18%, and GVHD for 17% and 19% of deaths in MSD and MUD recipients, respectively (Fig. 3c) .
Univariate and multivariate analyses results for the other outcomes are summarized in in the Supplemental Table and  Table 2 .
Discussion
Despite major improvements, HSCT still remains a highrisk procedure hampered by high morbidity and mortality, with important consequences on quality of life. Both disease recurrence and GVHD represent major post-transplant complications and should be considered when evaluating transplant outcomes. Classical endpoints such as LFS do not really reflect all transplant complications, as they only take into account disease relapse without considering GVHD which is, especially in its chronic form, a wellknown cause of late morbidity and mortality, with significant impairment of quality of life [18] .
The introduction of a new composite endpoint, named GRFS, in the transplant research field, aims to incorporate disease relapse, GVHD, and death from other causes in one single endpoint as an indirect measure of survival and quality of life after HSCT [9] .
In the current study, we retrospectively compared GRFS in one of the largest cohort of patients transplanted for intermediate or unfavorable cytogenetics from either MSD or 10/10 MUD. Owing to the previous data showing that HLA-mismatches might be associated with worse outcomes, we only included HLA-matched donors, which have been reported to have similar outcomes.
In line with previous studies, we observed a higher risk of both acute and chronic GVHD and of NRM in MUD as compared to MSD recipients, and a trend to a lower risk of relapse in MUD recipients [19, 20] . These results may be explained by the existence of mismatches in minor histocompatibility antigens for MUD recipients [3] .
To identify modifiable risk factors, which might impact on GRFS we also performed a risk factor analysis.
Differently from most studies having GRFS as primary endpoint, we chose to analyze only one type of hematologic malignancy, to have similar disease biology and more homogeneous results. In particular, we chose to select only patients with intermediate and poor cytogenetics in first CR as they unequivocally need HSCT [21] , to better represent a strategy commonly adopted in most hematological centers.
Holtan et al. [9] who were the first to describe GRFS, reported a large population of patients, both pediatric and adult, with different hematologic malignancies and disease status, including different types of donors. They found that adults had worse GRFS than pediatric patients, with the highest GRFS in those patients receiving bone marrow from MSD as compared to those receiving PBSC from MSD, UD graft or umbilical cord blood units. Moreover, they also found a lower GRFS in high-risk diseases but they do not provide details on GRFS according to the type of hematologic disease, such as AML. A limit of their GRFS definition is that they only considered events occurring during the first 12 months after allo-HSCT. Even if events such as chronic GVHD or disease relapse are known to mainly occur during the first year after HSCT, indeed, in some cases they can also appear later, especially since the introduction of RIC regimens. Subsequently, Ruggeri et al. introduced refined GRFS that might better reflect ongoing morbidity and quality of life after HSCT in registry studies, where details on immunosuppressive treatment are not always available. Moreover, immunosuppressive strategies and treatment timing are different according to centers, as there are some centers introducing treatment also in moderate forms to prevent progression to more severe forms. Therefore, introduction of immunosuppressive agents may not necessarily reflect GVHD severity and subsequently extensive chronic GVHD has been regarded as one of the refined GRFS events as these data are more frequently available and with the rationale that it better reflects ongoing mordibity than the need for immunosuppressive treatment.
Our results indicate that patients transplanted from MSD experience better GRFS and this may be attributable to higher incidence of both grade III-IV aGVHD and extensive cGVHD in MUD recipients. On the other hand, no significant differences in terms of disease control were found according to donor type, with similar RI and LFS.
These results are in line with Solh et al. [22] , who also found a lower GRFS in MUD as compared to MSD recipients at 2 years, with better GRFS in those patients receiving bone marrow as stem cell source, and worse GRFS in those with advanced diseases. However, as for Holtan et al., this study included different hematological malignancies with different disease status at the time of HSCT, which also explains the much lower GRFS observed in their series. Furthermore, in both studies the GRFS definition was not the refined GRFS reported by Ruggeri et al. [10] . The latter analyzed more than twenty thousand patients undergoing MSD or MUD transplant for AML in first or second CR, and found a GRFS of 40%. Similar to our results, relapse accounted for the main GRFS event, followed by extensive cGVHD, death from other causes and grade III-IV aGVHD. However, in that study, neither comparisons according to donor type nor a risk factor analysis were performed.
In our study we observed that, despite a rather promising OS of 69% and 65% for MSD and MUD recipients, respectively, only 44% of patients survived at 4 years after HSCT without experiencing at least one GRFS event, mainly represented by disease relapse and extensive cGVHD. When comparing outcomes of HSCT in patients with intermediate or poor-risk AML in first CR according to different donor types, Yoon et al. [23] found a similar OS of 63% in both MSD and MUD, with no differences in LFS.
According to the risk factor analysis, a lower GRFS was associated with the use of PBSC, in particular in relation to a higher incidence of cGVHD, as previously largely reported in studies investigating main transplant outcomes [12, 24, 25] .
A recent Japanese registry study found a similarly remarkably higher GRFS with the use of bone marrow, especially in MSD recipients and they also observed that use of in vivo TCD was associated with higher GRFS, mainly attributable to the lower incidence of GVHD, even if its use was counterbalanced by a higher RI [26] .
It is worth underlying that despite in vivo TCD being mainly used in MUD recipients, in our series the latter where the ones experiencing a worse GRFS when compared to MSD recipients, thus underlying the need to further optimize immunosuppressive strategies in this group of patients.
As largely reported, MUD experience worse outcomes as compared to MSD recipients, in part also explained by the existence of minor histocompatibility antigens [27] . Despite implement of immunosuppressive strategies in MUD recipients with strategies such as in vivo T-cell depletion, outcomes of MUD do not get to be equal to those from MSD. Optimization of immunosuppressive strategies in this context with use of different immunosuppressive platforms, such as for example post-transplant cyclophosphamide, may be investigated.
A recent retrospective study from the EBMT found an improved 2-year GRFS of 60% in MSD recipients receiving in vivo TCD, as compared to 40% in those not subjected to this procedure [28] .
Similarly, in a recent prospective study, the use of ATG in MSD recipients was associated with lower extensive cGVHD as compared to that in those not being treated with ATG (7.6% vs 52.4%), with a significantly larger number in the ATG group being off immunosuppression at 1 year after HSCT (91% vs 39%) [29] . They also describe a higher CI of cGVHD-relapse-free survival at 2 years in the ATG group (36.6% vs 16.8% in non ATG group, p = 0.005).
Furthermore, two non-modifiable risk factors were also identified in our cohort, these being an incremental age of 10 years and the presence of poor cytogenetics at diagnosis.
Importantly, despite not being related to a worse GRFS, in our series the RIC regimen remained a risk factor for a higher RI and NRM and lower aGVHD, as previously reported [11] .
One additional limitation of our study, being based on retrospective registry data, is that details on GVHD evolution, the exact type and duration of the immunosuppressive treatment were not available in many of the patients and thus could have not been taken into account in the analysis. Our study has also other the limitations of a retrospective registry analysis. Although patients were categorized by their disease risk and the multivariate modeling may have adjusted for various patient-, disease-, and transplantationrelated factors, there may be factors of importance that we have not been able to take into account, such as molecular biology at time of diagnosis.
Our findings support the use of GRFS as an interesting tool to assess transplantation outcomes, taking into consideration the transplant-mediated anti leukemic effect on the one hand, and the transplant-related toxicity, mainly represented by GVHD and related morbidity, on the other. According to our results, patients transplanted from MSD experience higher GRFS because of lower incidence of GVHD and infections.
Our results highlight that GRFS may be favorably influenced by the preferential use of BM grafts over PBSC. However, over the past decade, the latter have become the preferred stem cell source by donors and transplant centers, and this tendency may not easily and rapidly change. Therefore, efforts to reduce GVHD incidence, with future expectations of better outcomes even in patients receiving PBSC, are ongoing. Use of GRFS as a primary endpoint may be particularly interesting in those studies addressing GVHD.
Further clinical studies should investigate GRFS as a primary endpoint, especially those addressing GVHD. Moreover, identification of additional prognostic factors impacting on GRFS may guide in the near future for donor, conditioning or immunosuppression choices, and may help establish GRFS as the ultimate outcome parameter to assess the benefit of allogeneic transplantation, even in the setting of clinical trials.
